SCHEMBL15710641

SCHEMBL15710641

NCCC(C(=O)O)C(=O)O.[Na].[Na]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 3/20 0.55
GSR P00390 2/20 0.44
ENPEP Q07075 2/20 0.44
RNPEP Q9H4A4 1/20 0.42
CPB2 Q96IY4 3/20 0.41
ALDH1A1 P00352 1/20 0.37
GLRA1 P23415 1/20 0.37
SLC6A9 P48067 1/20 0.37
OR51E2 Q9H255 1/20 0.37
CYP1A2 P05177 2/20 0.36
GRIK1 P39086 2/20 0.36
SLC1A3 P43003 2/20 0.36
SLC1A2 P43004 2/20 0.36
SLC1A1 P43005 2/20 0.36
GRIK2 Q13002 2/20 0.36
GRM8 O00222 1/20 0.36
GRM6 O15303 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1118686 0.97 GABRR1 (0.57) GABRR1GSRENPEPRNPEPCPB2
SCHEMBL18342682 0.82 GABRR1 (0.50) GABRR1GSRENPEPRNPEPCPB2
SCHEMBL5813280 0.80 GABRR1 (0.54) GABRR1GSRENPEPRNPEPCPB2
SCHEMBL8125795 0.80 GABRR1 (0.48) GABRR1GSRENPEPRNPEPCPB2
SCHEMBL8166138 0.80 GABRR1 (0.54) GABRR1GSRENPEPRNPEPCPB2
SCHEMBL15710597 0.79 CPB2 (0.56) GABRR1GSRENPEPRNPEPCPB2
Hydrochloric Acid SCHEMBL7364749 0.78 GABRR1 (0.52) GABRR1GSRENPEPRNPEPCPB2
SCHEMBL1938544 0.78 GABRR1 (0.46) GABRR1GSRENPEPRNPEPCPB2
SCHEMBL1807063 0.77 GSR (0.65) GABRR1GSRENPEPRNPEPCPB2
SCHEMBL15710827 0.77 CPB2 (0.54) GABRR1GSRENPEPRNPEPCPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2740738-B1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) 2018-03-28 EP disclosed
US-9138421-B2 Platinum compounds for treating cell proliferative diseases, preparation method and use thereof BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2015-09-22 US disclosed
EP-2740738-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF Beijing FSwelcome Technology Development Co., Ltd. (CN) 2014-06-11 EP disclosed
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2014-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF PCNA, POLI, MKI67 GABRR1 4168/4885GSR 810/4885ENPEP 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.